Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Weighted Average) (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $137.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.76% year-over-year to $137.0 million, compared with a TTM value of $137.0 million through Dec 2025, up 9.76%, and an annual FY2025 reading of $133.8 million, up 11.67% over the prior year.
  • Shares Outstanding (Weighted Average) was $137.0 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $133.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $139.0 million in Q2 2025 and bottomed at $103.6 million in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $115.0 million, with a median of $106.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 1.12% in 2022, then rose 16.23% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $104.5 million in 2021, then grew by 1.44% to $106.0 million in 2022, then increased by 1.3% to $107.4 million in 2023, then rose by 16.23% to $124.8 million in 2024, then grew by 9.76% to $137.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ARWR at $137.0 million in Q4 2025, $133.8 million in Q3 2025, and $139.0 million in Q2 2025.